Major music publishers have launched a massive copyright infringement lawsuit against AI company Anthropic, alleging its Claude AI was trained on a dataset of over 20,000 pirated songs, in a case that could redefine the rules for AI development.
Facing one of the longest downturns in industry history, LyondellBasell reported Q2 2025 earnings of $0.62 per share, outlining a disciplined strategy focused on cash conservation, portfolio optimization in Europe, and a pivot towards circular and low-carbon solutions to emerge stronger from the cycle.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
A patent lawsuit filed by Solos Technology against Meta Platforms, Oakley, and EssilorLuxottica targets core smart glasses technology, posing significant risks to Meta's wearables strategy and valuation.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
Venture capitalist Chamath Palihapitiya scored a monumental win with Nvidia's $20.6 billion purchase of AI chipmaker Groq, yet the investor reveals a profound sense of melancholy, highlighting the psychological complexities behind blockbuster deals.
Spotify and major record labels have filed a staggering $13 trillion lawsuit against Anna's Archive, alleging the platform facilitated the theft of metadata and audio files representing nearly all commercial recordings. The case raises profound questions about digital piracy and copyright enforcement in the streaming era.
Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Analysts at Susquehanna upgrade Arm Holdings to Positive, citing transformative deals with OpenAI and Meta. The firm projects a new AI XPU could generate over $1 billion in annual royalties, signaling a major shift beyond Arm's mobile roots.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
The educational streaming service CuriosityStream Inc. (NASDAQ: CURI) is drawing strong analyst support following robust Q3 2025 results, with a consensus 'Strong Buy' rating and a $6 price target highlighting significant growth potential from its current trading level.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
A dramatic surge in SuperX AI Technology's share price has spotlighted its concentrated ownership structure, with private companies holding a dominant 34% stake and reaping the largest rewards from the recent rally. As the AI-driven healthcare sector heats up, investor attention turns to who holds the reins at this promising but closely held firm.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
Unity Software's new in-app web store integration with Coda could empower developers to bypass traditional marketplace fees, potentially altering the company's revenue streams and addressing its persistent valuation gap amid volatile stock performance.
